“we are currently evaluating, I think it's twenty, twenty five different, compounds, which resource from all different sources, from companies, from academia, from other, nonprofit organizations, which, have supported such therapies, for their disease, and which we evaluate again now in our dedicated CROs head to head in order to identify the most promising candidate or candidates, which we will then move forward into first, first in men, clinical studies.”
→ Read the source episode
At least one read-through molecule candidate from Read On Therapeutics enters first-in-human clinical trials.
Jean Mack predicts Phase 2 will enroll patients across Australia, potentially Europe, and the United States
Deborah Research is supporting development of a self-cooling sole for sneakers to address blister problems in EB patients.
Jean Mack predicts GAIN's IND will be cleared by the FDA within weeks and Phase 2 will begin in Q3 2026
Lu Gao predicts Therona will file INDs in parallel in the US and China in Q4 2026
Andy Parker predicts StepPharma will raise additional funding within next six months (by January 2027).
Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.